A Long-Term Study of JNT-517 in Participants With Phenylketonuria
Eligible age
4+ yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this Phase 3, open-label study is to evaluate the long-term safety of JNT-517 in pediatric and adult participants with Phenylketonuria (PKU) after completion of either Study JNT517-101 (NCT05781399) or JNT517-201 (NCT06637514) as well as participants who have not participated in a prior JNT-517 study. In this trial, all participants will receive JNT-517 using age- and weight-banded dosing as outlined in the protocol, regardless of any dose received in a previous study.
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Where it's recruiting
Gainesville · Tampa
Portland
Pittsburgh
Dallas · Houston
Salt Lake City
Source: ClinicalTrials.gov · NCT06628128 · last updated 2026-05-01